Hyloris And Purna Strike Value-Added Development Deal
Miconazole And Domiphen Bromide Combination Will Treat Vulvovaginal Candidiasis
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.
You may also be interested in...
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.